Search | Clinical Trials Finder

Conditions: Relapsing Multiple Sclerosis, Relapsing Remitting Multiple Sclerosis, Secondary Progressive Multiple Sclerosis
Interventions: Autologous Hematopoietic Stem Cell Transplantation, Best Available Therapy (BAT); Procedure · Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 55 Years
Enrollment: 156 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2029
U.S. locations: 22
States / cities: Palo Alto, California • Aurora, Colorado • Evanston, Illinois + 17 more

Conditions: Relapsing Multiple Sclerosis, Clinically Isolated Syndrome
Interventions: Ocrelizumab; Drug
Lead sponsor: University of California, San Francisco; Other
Eligibility: 18 Years to 50 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2027
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Multiple Sclerosis
Interventions: Ocrelizumab, Placebo for Ocrelizumab; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 55 Years
Enrollment: 123 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2032
U.S. locations: 13
States / cities: New Haven, Connecticut • Washington D.C., District of Columbia • Chicago, Illinois + 10 more

Conditions: Relapsing Multiple Sclerosis, Primary Progressive Multiple Sclerosis
Interventions: Ocrelizumab IV, Ocrelizumab SC, Methylprednisolone IV, Diphenhydramine IV, Dexamethasone given orally, Desloratadine given orally; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 236 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2025
U.S. locations: 7
States / cities: Maitland, Florida • Tampa, Florida • Baltimore, Maryland + 4 more

Conditions: Multiple Sclerosis
Interventions: Ocrelizumab; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 10 Years to 18 Years
Enrollment: 23 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2029
U.S. locations: 5
States / cities: Aurora, Colorado • Washington D.C., District of Columbia • Boston, Massachusetts + 2 more

Conditions: Multiple Sclerosis
Interventions: High Efficacy Therapy (HET), Non High Efficacy Therapy (Non-HET); Other
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years to 100 Years
Enrollment: 4,361 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021
U.S. locations: 1
States / cities: East Hanover, New Jersey

Conditions: Multiple Sclerosis, Healthy
Interventions: Blood draw; Other
Lead sponsor: Brigham and Women's Hospital; Other
Eligibility: 18 Years to 65 Years
Enrollment: 159 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2023
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Multiple Sclerosis, Immune System Diseases
Interventions: ocrelizumab; Drug
Lead sponsor: University of Chicago; Other
Eligibility: 18 Years to 65 Years
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2019
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Multiple Sclerosis
Interventions: Ocrelizumab; Drug
Lead sponsor: Brigham and Women's Hospital; Other
Eligibility: 18 Years and older
Enrollment: 800 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Relapsing Multiple Sclerorsis, Multiple Sclerosis, Primary Progressive
Interventions: Ocrelizumab, Lumbar Puncture, Methyloprednisolone, Antihistamine; Drug · Procedure
Lead sponsor: Genentech, Inc.; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 131 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2023
U.S. locations: 12
States / cities: Palo Alto, California • San Francisco, California • Aurora, Colorado + 9 more

Conditions: Multiple Sclerosis
Interventions: 11C-PBR28; Drug
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years to 65 Years
Enrollment: 22 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2025
U.S. locations: 1
States / cities: Charlestown, Massachusetts

Conditions: Multiple Sclerosis, Covid19
Interventions: Not listed
Lead sponsor: St. Barnabas Medical Center; Other
Eligibility: 18 Years to 65 Years
Enrollment: 45 participants
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: Livingston, New Jersey

Conditions: Multiple Sclerosis
Interventions: SARS-COV-2 mRNA Vaccine; Drug
Lead sponsor: NYU Langone Health; Other
Eligibility: 18 Years to 65 Years
Enrollment: 64 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 2
States / cities: Denver, Colorado • New York, New York

Conditions: Multiple Sclerosis
Interventions: Ocrelizumab; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years and older
Enrollment: 1,300 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 50
States / cities: Phoenix, Arizona • Laguna Hills, California • Palo Alto, California + 41 more

Conditions: Multiple Sclerosis
Interventions: Ofatunumab; Other
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years to 99 Years
Enrollment: 2,101 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2021
U.S. locations: 1
States / cities: East Hanover, New Jersey

Conditions: Relapsing-remitting Multiple Sclerosis
Interventions: Ocrelizumab, Ocrelizumab Placebo, Fingolimod, Fingolimod Placebo; Drug · Other
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 10 Years to 17 Years
Enrollment: 188 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2029
U.S. locations: 10
States / cities: La Jolla, California • Aurora, Colorado • Washington D.C., District of Columbia + 7 more

Conditions: Multiple Sclerosis
Interventions: Ocrelizumab Test Formulation, Ocrelizumab Reference Formulation; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 193 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2030
U.S. locations: 9
States / cities: Carlsbad, California • Fort Collins, Colorado • Maitland, Florida + 6 more

Conditions: Multiple Sclerosis, Primary Progressive
Interventions: Fenebrutinib, Ocrelizumab, Placebo matched to ocrelizumab, Placebo matched to fenebrutinib; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 985 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2027
U.S. locations: 43
States / cities: Homewood, Alabama • Berkeley, California • Fullerton, California + 40 more

Conditions: Multiple Sclerosis
Interventions: Clinical Questionnaires, Semi-Structured Interviews, Ocrevus Zunovo; Other · Drug
Lead sponsor: Northwestern University; Other
Eligibility: 18 Years and older
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Multiple Sclerosis
Interventions: Ocrelizumab Co-formulated With rHuPH20; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 75 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 6
States / cities: Carlsbad, California • Maitland, Florida • Tampa, Florida + 3 more

Conditions: Multiple Sclerosis, Relapsing-Remitting
Interventions: Natalizumab/natalizumab-sztn, Alemtuzumab, Ocrelizumab, Rituximab/rituximab-arrx/rituximab-abbs/rituximab-pvvr, Cladribine, Ofatumumab, Ublituximab-xiiy, Ocrelizumab and hyaluronidase-ocsq, Glatiramer acetate, Interferons (intramuscular, subcutaneous, pegylated) Teriflunomide, Fumarates (dimethyl, diroximel, monomethyl) Fingolimod, Siponimod, Ozanimod, Ponesimod; Other
Lead sponsor: Johns Hopkins University; Other
Eligibility: 18 Years to 60 Years
Enrollment: 900 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2026
U.S. locations: 47
States / cities: Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 38 more

Conditions: Multiple Sclerosis, RRMS, Relapsing Remitting MS
Interventions: HP 13C pyruvate injection, MRI Scanner; Drug · Device
Lead sponsor: Ari Green; Other
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2029
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Multiple Sclerosis, Relapsing-Remitting, Fatigue
Interventions: TENOFOVIR ALAFENAMIDE FUMARATE 25 Mg ORAL TABLET [VEMLIDY], Placebo; Drug
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2025
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Multiple Sclerosis, Relapsing-Remitting
Interventions: Ocrelizumab; Drug
Lead sponsor: Genentech, Inc.; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 608 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2019
U.S. locations: 67
States / cities: Cullman, Alabama • Phoenix, Arizona • Tucson, Arizona + 59 more

Search by objective public record fields.

Best Available Therapy Versus Autologous Hematopoietic Stem Cell Transplant for Multiple Sclerosis (BEAT-MS)

Impact of Ocrelizumab on Cerebrospinal Fluid Biomarkers at Multiple Sclerosis Onset

Ocrelizumab Discontinuation in Relapsing Multiple Sclerosis

A Phase III, Non-Inferiority, Randomized, Open-Label, Parallel Group, Multicenter Study To Investigate The Pharmacokinetics, Pharmacodynamics, Safety And Radiological And Clinical Effects Of Subcutaneous Ocrelizumab Versus Intravenous Ocrelizumab In Patients With Multiple Sclerosis

A Study of Ocrelizumab in Children and Adolescents With Relapsing-Remitting Multiple Sclerosis

Risk Perception in Multiple Sclerosis

COVID-19 Vaccine Response in Treated MS Patients

Mechanism of Action of Ocrelizumab in Multiple Sclerosis

Ocrelizumab Access by Socio-Economic Status

Study to Explore the Mechanism of Action of Ocrelizumab and B-Cell Biology in Participants With Relapsing Multiple Sclerosis (RMS) or Primary Progressive Multiple Sclerosis (PPMS)

Effect of Ocrelizumab on Neuroinflammation in Multiple Sclerosis as Measured by 11C-PBR28 MR-PET Imaging of Microglia Activation

Effect of Disease Modifying Therapy on Antibody Response to COVID19 Vaccination in Multiple Sclerosis

Vaccine-generated Immunity in Ocrelizumab-treated Patients: Longitudinal Assessments (VIOLA)

A Rollover Study to Evaluate the Long-Term Safety and Efficacy of Ocrelizumab In Patients With Multiple Sclerosis

Characterization of Early Patients Initiating Ofatumumab for Treatment of Multiple Sclerosis.

A Study to Evaluate Safety and Efficacy of Ocrelizumab in Comparison With Fingolimod in Children and Adolescents With Relapsing-remitting Multiple Sclerosis (RRMS)

A Study to Assess Bioequivalence of Two Subcutaneous (SC) Formulations of Ocrelizumab in Participants With Multiple Sclerosis (MS)

A Study to Evaluate the Efficacy and Safety of Fenebrutinib Compared With Ocrelizumab in Adult Participants With Primary Progressive Multiple Sclerosis

Ocrevus Zunovo for MS: Mixed Methods

A Study to Investigate the Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Pharmacodynamics of a New Subcutaneous Formulation of Ocrelizumab in Participants With Multiple Sclerosis

Traditional Versus Early Aggressive Therapy for Multiple Sclerosis Trial

Hyperpolarized Carbon Metabolic Imaging in Multiple Sclerosis

Tenofovir Alafenamide for Treatment of Symptoms and Neuroprotection in Relapsing Remitting Multiple Sclerosis

A Study of Ocrelizumab in Participants With Relapsing Remitting Multiple Sclerosis (RRMS) Who Have Had a Suboptimal Response to an Adequate Course of Disease-Modifying Treatment (DMT)